CenterBook Partners LP Makes New $4.69 Million Investment in Codexis, Inc. (NASDAQ:CDXS)

CenterBook Partners LP purchased a new position in shares of Codexis, Inc. (NASDAQ:CDXS) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 982,848 shares of the biotechnology company’s stock, valued at approximately $4,688,000. CenterBook Partners LP owned about 1.21% of Codexis as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. FMR LLC increased its position in Codexis by 1.2% during the third quarter. FMR LLC now owns 4,497,090 shares of the biotechnology company’s stock worth $13,851,000 after buying an additional 51,822 shares during the last quarter. State Street Corp boosted its stake in shares of Codexis by 2.7% during the 3rd quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company’s stock worth $4,778,000 after acquiring an additional 41,480 shares in the last quarter. Barclays PLC boosted its stake in shares of Codexis by 51.1% during the 3rd quarter. Barclays PLC now owns 207,628 shares of the biotechnology company’s stock worth $640,000 after acquiring an additional 70,255 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Codexis by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company’s stock valued at $5,065,000 after acquiring an additional 11,082 shares during the last quarter. Finally, Empire Financial Management Company LLC raised its stake in shares of Codexis by 4.7% in the 3rd quarter. Empire Financial Management Company LLC now owns 222,952 shares of the biotechnology company’s stock valued at $687,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors own 78.54% of the company’s stock.

Codexis Stock Down 4.4 %

Shares of Codexis stock opened at $1.97 on Wednesday. Codexis, Inc. has a 12-month low of $1.90 and a 12-month high of $6.08. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The stock has a 50 day moving average price of $3.30 and a two-hundred day moving average price of $3.90. The stock has a market capitalization of $163.19 million, a P/E ratio of -2.26 and a beta of 2.35.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The firm had revenue of $21.46 million for the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. Equities analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.